Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.
Press releases published on April 17, 2025
LifeMD Expands Insurance Acceptance to Medicare Beneficiaries for Qualifying Virtual Primary Care, Including in its Weight Loss Programs
GlobeNewswire
·
April 17, 2025
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced expanded acceptance of insurance to Medicare beneficiaries for qualifying care. Initially available to more than …
Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience
GlobeNewswire
·
April 17, 2025
-- Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate -- -- One third of patients taking immediate-release, twice-nightly sodium oxybate discontinued treatment, most …
InnovAge Champions PACE at State Capitols to Protect Critical Care for Seniors
GlobeNewswire
·
April 17, 2025
DENVER, April 17, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), the nation’s largest provider of the Program of All-inclusive Care for the Elderly (PACE) based on participants served, has engaged staff, nationwide, to …
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors
GlobeNewswire
·
April 17, 2025
SAN DIEGO, April 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering targeted antitumor virotherapies, announced today that the U.S. Food and Drug Administration (FDA) …
Contrave Weight Loss: Top OTC Contrave Weight Loss Medication Alternative From PhenQ
GlobeNewswire
·
April 17, 2025
Albany, New York, April 17, 2025 (GLOBE NEWSWIRE) -- If you're facing challenges with your weight, you're in good company. As per the Centers for Disease Control and Prevention (CDC), a substantial 73.6% of adults aged 20 years and above are grappling with …
Victoza Weight Loss: Buy OTC Victoza For Weight Loss Medication Alternative From PhenQ – Real Reviews
GlobeNewswire
·
April 17, 2025
Albany, New York, April 17, 2025 (GLOBE NEWSWIRE) -- In thе last 30 yеars and thе Amеricas havе witnеssеd a significant surgе in adults diagnosеd with diabеtеs and attributеd to еscalatin ratеs of obеsity and poor diеtary habits and and sеdеntary …
Best Berberine Supplement: Top Berberine Supplements For Weight Loss & Blood Sugar From Sugar Defender
GlobeNewswire
·
April 17, 2025
Albany, New York, April 17, 2025 (GLOBE NEWSWIRE) -- What is Berberine? Berberine is an alkaloid found in plants, such as barberry. Traditional Asian medicines have long recognized the health advantages of this alkaloid. Berberine has gained popularity as …
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism
GlobeNewswire
·
April 17, 2025
CELEBRATION, Fla., April 17, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announces the publication of “ …
Injectable Drug Delivery Devices Market Set to Reach $317.2 Billion by 2029
GlobeNewswire
·
April 17, 2025
Boston, April 17, 2025 (GLOBE NEWSWIRE) -- BCC Research reveals in its new report, Global Injectable Drug Delivery Devices Market, the market for injectable drug delivery devices is projected to grow to $317.2 billion by 2029 at a five-year compound annual …
Amwell® to report first quarter 2025 operating results
GlobeNewswire
·
April 17, 2025
BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in digital care, will report first quarter 2025 operating results after stock market trading hours on Thursday, May 1 2025. Following the distribution of the earnings alert via wire …
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
GlobeNewswire
·
April 17, 2025
If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated for all other anti-VEGF therapies Potential for as …
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025
GlobeNewswire
·
April 17, 2025
CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference …
New Study Reveals Promise of Text-Based Mental Health Support App Counslr in Decreasing Barriers to Mental Health Support
GlobeNewswire
·
April 17, 2025
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Counslr, a leading B2B mental health and wellness platform, announced today the publication of a new study in JMIR Formative Research titled “Evaluating User Engagement with a Real-Time, Text-Based Digital …
Tilray Brands Announces Proposed Reverse Stock Split and Corresponding Special Meeting of Stockholders
GlobeNewswire
·
April 17, 2025
NEW YORK and LEAMINGTON, Ontario, April 17, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of beverage, cannabis and wellness …
Enovis to Host First Quarter 2025 Results Conference Call on May 8th
GlobeNewswire
·
April 17, 2025
Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 …
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
GlobeNewswire
·
April 17, 2025
BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today …
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
GlobeNewswire
·
April 17, 2025
SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John …
AAFA Announces Innovative Program in Texas Serving Communities Facing Highest Rates of Asthma
GlobeNewswire
·
April 17, 2025
Washington, DC, April 17, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) announces an innovative new collaboration with Health Care Originals, Inc. (HCO) and Rabbit Air as part of AAFA’s Health Equity Advancement and …
Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions
GlobeNewswire
·
April 17, 2025
Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in …
Ostarine (MK 2866) PCT: Ostarine Before & After Result Benefits - Legal Ostarine MK-2866 SARM For Sale From CrazyBulk
GlobeNewswire
·
April 17, 2025
Albany, New York, April 17, 2025 (GLOBE NEWSWIRE) -- Ostarine, also known as MK-2866, is a SARM that is considered to be on the milder end of the spectrum and is often used by novices. Many people take this to mean that you do not need to complete the PCT …